Avid Bioservices Financials
CDMO Stock | USD 12.46 0.02 0.16% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Current Ratio | 2.64 | 1.69 |
|
|
Investors should never underestimate Avid Bioservices' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Avid Bioservices' cash flow, debt, and profitability to make informed and accurate decisions about investing in Avid Bioservices.
Net Income |
|
Avid | Select Account or Indicator |
Understanding current and past Avid Bioservices Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Avid Bioservices' financial statements are interrelated, with each one affecting the others. For example, an increase in Avid Bioservices' assets may result in an increase in income on the income statement.
Avid Bioservices Stock Summary
Avid Bioservices competes with Anebulo Pharmaceuticals, Adagene, Acrivon Therapeutics,, AnaptysBio, and Mineralys Therapeutics,. Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. Avid Bioservices, Inc. was incorporated in 1981 and is headquartered in Tustin, California. Avid Bioservices operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 321 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | US05368M1062 |
CUSIP | 05368M106 713661304 713661502 713661106 878517309 |
Location | California; U.S.A |
Business Address | 14191 Myford Road, |
Sector | Biotechnology |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.avidbio.com |
Phone | 714 508 6100 |
Currency | USD - US Dollar |
Avid Bioservices Key Financial Ratios
Return On Equity | -1.16 | ||||
Profit Margin | (1.01) % | ||||
Operating Margin | (0.06) % | ||||
Price To Sales | 5.59 X | ||||
Revenue | 139.91 M |
Avid Bioservices Key Balance Sheet Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Total Assets | 265.5M | 429.8M | 451.1M | 336.6M | 387.0M | 406.4M | |
Other Current Liab | 8.2M | 9.5M | 11.2M | 8.7M | 10.0M | 10.5M | |
Net Debt | (51.7M) | 56.4M | 150.7M | 169.7M | 195.2M | 204.9M | |
Retained Earnings | (559.9M) | (431.4M) | (430.8M) | (571.9M) | (514.7M) | (488.9M) | |
Accounts Payable | 9.3M | 9.5M | 24.6M | 20.7M | 23.8M | 25.0M | |
Net Receivables | 25.0M | 25.9M | 27.9M | 29.0M | 33.4M | 35.0M | |
Other Current Assets | 1.1M | 1.9M | 2.1M | 6.5M | 7.5M | 7.9M | |
Total Liab | 187.8M | 255.3M | 261.6M | 275.7M | 317.0M | 332.9M | |
Total Current Assets | 207.8M | 180.0M | 112.5M | 104.0M | 119.6M | 125.6M | |
Cash | 169.9M | 126.2M | 38.5M | 38.1M | 43.8M | 36.3M | |
Inventory | 11.9M | 26.1M | 43.9M | 30.4M | 34.9M | 36.7M | |
Short Term Debt | 2.7M | 3.5M | 142.0M | 2.8M | 3.2M | 3.1M | |
Other Assets | 652K | 1.6M | 120.1M | 118.5M | 136.2M | 143.0M | |
Common Stock | 61K | 62K | 63K | 64K | 57.6K | 95.3K | |
Net Tangible Assets | 41.9M | 77.7M | 174.5M | 189.5M | 217.9M | 228.8M | |
Capital Surpluse | 612.9M | 637.5M | 605.8M | 620.2M | 713.3M | 623.0M |
Avid Bioservices Key Income Statement Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Interest Expense | 1.2M | 2.7M | 2.6M | 4.3M | 5.0M | 5.2M | |
Total Revenue | 95.9M | 119.6M | 149.3M | 139.9M | 160.9M | 168.9M | |
Gross Profit | 29.3M | 36.6M | 31.5M | 7.3M | 8.4M | 8.6M | |
Operating Income | 8.9M | 10.9M | (2.6M) | (18.7M) | (16.8M) | (17.7M) | |
Ebit | 12.2M | 15.4M | 3.7M | (22.6M) | (20.3M) | (21.3M) | |
Ebitda | 15.7M | 19.9M | 10.9M | (11.5M) | (13.2M) | (13.9M) | |
Cost Of Revenue | 66.6M | 82.9M | 117.8M | 132.6M | 152.5M | 160.1M | |
Income Before Tax | 11.2M | 12.7M | 2.0M | (26.9M) | (31.0M) | (32.5M) | |
Net Income | 11.2M | 127.7M | 560K | (140.8M) | (126.7M) | (120.3M) | |
Income Tax Expense | (2.3M) | (115.0M) | 1.4M | 113.8M | 130.9M | 137.4M | |
Net Interest Income | (1.0M) | (2.7M) | (2.6M) | (4.3M) | (3.9M) | (3.7M) |
Avid Bioservices Key Cash Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Change To Inventory | (988K) | (14.2M) | (17.8M) | 13.5M | 12.2M | 12.8M | |
Change In Cash | 133.7M | (43.7M) | (87.6M) | (786K) | (707.4K) | (672.0K) | |
Free Cash Flow | 21.3M | (46.9M) | (90.5M) | (20.9M) | (18.8M) | (19.7M) | |
Depreciation | 3.5M | 4.5M | 7.2M | 11.1M | 12.8M | 13.4M | |
Other Non Cash Items | 916K | 1.4M | 1.2M | 3.6M | 3.2M | 3.4M | |
Capital Expenditures | 9.9M | 56.4M | 77.6M | 31.8M | 36.6M | 38.4M | |
Net Income | 11.2M | 127.7M | 560K | (140.8M) | (126.7M) | (120.3M) | |
End Period Cash Flow | 170.3M | 126.5M | 38.9M | 38.1M | 43.8M | 37.2M | |
Change Receivables | (1.2M) | (10.2M) | (1.7M) | 2.2M | 2.0M | 2.1M | |
Net Borrowings | 4.3M | 134.0M | (162K) | (505K) | (580.8K) | (551.7K) | |
Change To Netincome | 2.5M | 3.9M | (107.3M) | 12.6M | 11.3M | 11.9M | |
Investments | (9.9M) | (56.4M) | (77.6M) | (31.8M) | (28.6M) | (30.1M) |
Avid Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Avid Bioservices's current stock value. Our valuation model uses many indicators to compare Avid Bioservices value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Avid Bioservices competition to find correlations between indicators driving Avid Bioservices's intrinsic value. More Info.Avid Bioservices is rated below average in return on equity category among its peers. It is number one stock in return on asset category among its peers . At this time, Avid Bioservices' Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Avid Bioservices' earnings, one of the primary drivers of an investment's value.Avid Bioservices Systematic Risk
Avid Bioservices' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Avid Bioservices volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty with a total number of output elements of thirty-one. The Beta measures systematic risk based on how returns on Avid Bioservices correlated with the market. If Beta is less than 0 Avid Bioservices generally moves in the opposite direction as compared to the market. If Avid Bioservices Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Avid Bioservices is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Avid Bioservices is generally in the same direction as the market. If Beta > 1 Avid Bioservices moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Avid Bioservices Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Avid Bioservices' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Avid Bioservices growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Avid Bioservices January 30, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Avid Bioservices help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Avid Bioservices. We use our internally-developed statistical techniques to arrive at the intrinsic value of Avid Bioservices based on widely used predictive technical indicators. In general, we focus on analyzing Avid Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Avid Bioservices's daily price indicators and compare them against related drivers.
Downside Deviation | 0.8096 | |||
Information Ratio | 0.1233 | |||
Maximum Drawdown | 13.69 | |||
Value At Risk | (1.45) | |||
Potential Upside | 1.93 |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Avid Bioservices. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in Avid Stock, please use our How to Invest in Avid Bioservices guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avid Bioservices. If investors know Avid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Avid Bioservices listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.80) | Earnings Share (2.41) | Revenue Per Share | Quarterly Revenue Growth 0.065 | Return On Assets |
The market value of Avid Bioservices is measured differently than its book value, which is the value of Avid that is recorded on the company's balance sheet. Investors also form their own opinion of Avid Bioservices' value that differs from its market value or its book value, called intrinsic value, which is Avid Bioservices' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Avid Bioservices' market value can be influenced by many factors that don't directly affect Avid Bioservices' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Avid Bioservices' value and its price as these two are different measures arrived at by different means. Investors typically determine if Avid Bioservices is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Avid Bioservices' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.